Nanobiotix S.A. (NBTX)

NASDAQ: NBTX · IEX Real-Time Price · USD
8.98
-0.03 (-0.33%)
At close: Jan 19, 2022 4:00 PM
8.29
-0.69 (-7.68%)
After-hours:Jan 21, 2022 4:00 PM EST

Company Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer.

The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues.

It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer.

Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.
Nanobiotix Logo
CountryFrance
Founded2003
IPO DateDec 11, 2020
IndustryBiotechnology
SectorHealth Care
Employees98
CEOLaurent Levy

Contact Details

Address:
60 rue de Wattignies
Paris, Ile De France 75012
France
Phone33 1 40 26 04 70
Websitenanobiotix.com

Stock Details

Ticker SymbolNBTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyEUR
IPO Price$13.50
CIK Code1760854

Key Executives

NamePosition
Laurent Levy Ph.D.Co-Founder, President of the Executive Board and Chief Executive Officer
Anne-Juliette Hermant M.A.Chief People Officer and Member of Executive Board
Prof. Para Prasad Ph.D.Co-Founder and Member of Scientific Board
Earl J. Bergey Ph.d.Co-Founder
Bart Van RhijnChief Financial Officer and Member of Executive Board
Alain DostieChief Operating Officer
Kathryn M. McNeilSenior Vice President of Investor Relations
Brandon OwensVice President of Strategic Marketing and Corporate Communication
Elsa BorghiHead of Innovation and Drug Discovery
Sarah GaubertHead of Communication and Public Affairs Department

Latest SEC Filings

DateTypeTitle
Jan 11, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jan 10, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jan 5, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jan 4, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 8, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 17, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 9, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 8, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 3, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Oct 25, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings